Search
Guvacine
go.drugbank.com/drugs/DB08848ExperimentalGuvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalCurrently, ramosetron is only approved for use Japan and in certain Southeast Asian countries. … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions.
Firocoxib
go.drugbank.com/drugs/DB09217ExperimentalVet approvedFirocoxib is not intended or approved for use in human medicine. … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox.
Gemopatrilat
go.drugbank.com/drugs/DB20954ExperimentalGemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemMetergoline
go.drugbank.com/drugs/DB13520Approved] premenstrual dysphoric disorder in women and antianxiety treatment. … [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
AVI-4557
go.drugbank.com/drugs/DB05447Experimentalin clearance and an increase in maximal blood concentration (Cmax). … Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and longer availability of the drug in the patient's system through a decrease